HIV/AIDS

AMDS news November 2004 - July 2005

Action needed to lower prices of antiretroviral treatment in Commonwealth of Independent States region
From 24-25 February, the Commonwealth of Independent Sates (CIS) held a meeting in Baku, Azerbaijan to call for improved access to treatment for people living with HIV. A range of international organisations attended the meeting and urged governments in CIS countries to lower prices for antiretroviral drugs.
Full story

Dedication accelerates access to US$ 280 million for procurement and supply management (PSM)
Six countries in sub-Saharan Africa will have earlier access to a total of US$ 280 million from the Global Fund to fight AIDS, TB and Malaria (GFATM) to strengthen their national PSM systems and buy and distribute ARV drugs after having completed PSM plans in record time.
Full story

Two Cipla AIDS medicines back on WHO prequalification list
The World Health Organization (WHO) is reinstating two antiretrovirals manufactured by Cipla Ltd., India, in its list of prequalified medicines. The two medicines (which are used in the treatment of AIDS) had been delisted by WHO in May this year due to non-compliance with international standards at the contract research organizations (CROs) hired by Cipla to conduct bioequivalence tests on the products.
Full story

Hetero Drugs Ltd withdraws antiretrovirals from WHO prequalification list for further review
19 November 2004 - Following an inspection by the World Health Organization (WHO), generic manufacturer Hetero Drugs Limited, in Hyderbad, India, is withdrawing six antiretrovirals from the WHO prequalification list in order to review data on their bioequivalence.
Full story ¦ Guidance in en ¦ Guidance in es

Guidance on removal of Ranbaxy ARV products from the Prequalification list
11 November 2004 - WHO departments of Essential Drugs and Medicines Policy and HIV/AIDS issued today an information and guidance to national authorities, doctors and patients on the removal of Ranbaxy products from WHO Prequalification.
Full guidance (russian, chinese, arabic and spanish versions are enclosed)


Share